Ipamorelin Perimenopause Support Protocol: Dosing, Timing, Labs, and What to Expect

Why Perimenopause Disrupts GH Pulsatility

Growth hormone secretion does not wait for menopause to fall. Somatotroph pulse amplitude begins declining during the late reproductive years, tracking closely with the drop in estradiol that defines perimenopause. A 2000 analysis by Veldhuis et al. Published in the Journal of Clinical Endocrinology and Metabolism demonstrated that GH pulse amplitude in women correlates positively with estradiol concentrations across the reproductive lifespan, meaning the perimenopausal estrogen fluctuation directly suppresses overnight GH peaks [1].

That GH decline has downstream consequences. IGF-1 falls, lean mass decreases, visceral adiposity rises, and slow-wave sleep shortens. Each of these changes mirrors what perimenopausal women report clinically: unexplained weight gain concentrated around the abdomen, fatigue that is not explained by thyroid dysfunction, and sleep that no longer feels restorative.

The GH-Sleep Link in Midlife Women

Slow-wave (stage N3) sleep is the primary physiological trigger for endogenous GH release. A cross-sectional study of 149 healthy women aged 40 to 60, published in Sleep (Moline et al., 2003), found that perimenopausal women spent significantly less time in slow-wave sleep than premenopausal controls, with a concurrent reduction in nocturnal GH area under the curve [2]. Shorter slow-wave duration predicted lower morning IGF-1 even after controlling for BMI.

This bidirectional relationship matters for protocol design. Administering ipamorelin at bedtime targets the natural GH pulse window and may reinforce, rather than override, residual physiological rhythms.

Why IGF-1 Is the Practical Surrogate

Measuring GH directly is impractical in clinical settings because secretion is pulsatile and the half-life of GH is roughly 20 minutes. IGF-1, produced primarily by the liver in response to GH stimulation, has a half-life of approximately 15 hours and provides a stable 24-hour integrative signal. The Endocrine Society's 2019 clinical practice guideline on GH deficiency in adults endorses serum IGF-1 as the primary biochemical marker for monitoring GH axis activity [3].

What Ipamorelin Does Differently from Other GHRPs

Ipamorelin is a pentapeptide GHRP that selectively binds the ghrelin receptor (GHS-R1a) to stimulate GH release from pituitary somatotrophs. It stands apart from older GHRPs because it does not meaningfully raise cortisol or prolactin at clinical doses. GHRP-6, by contrast, produces a dose-dependent ACTH and cortisol spike that is clinically relevant in stress-sensitive perimenopausal women who already have dysregulated HPA axis activity [4].

Selectivity Profile

A 1998 pharmacological characterization by Raun et al. In European Journal of Endocrinology showed that ipamorelin produced GH release comparable to GHRP-6 in rat pituitary cell assays while causing no statistically significant change in ACTH, cortisol, or prolactin at doses up to 500 mcg/kg [5]. That selectivity profile is the primary reason practitioners favor ipamorelin over GHRP-2 or GHRP-6 in populations where HPA axis stability matters.

Comparison with MK-0677 (Ibutamoren)

MK-0677 (ibutamoren) is an oral GHS-R1a agonist with the strongest RCT data in the class. The Phase II trial by Murphy et al. (Journal of Clinical Endocrinology and Metabolism, 1998, N=32 elderly subjects) showed that 25 mg/day MK-0677 raised IGF-1 by 39% and increased fat-free mass by 1.5 kg at 12 months compared to placebo, with no significant change in cortisol [6]. Ipamorelin works through the same receptor by a different chemical route. Because no head-to-head RCT comparing ipamorelin directly to MK-0677 in perimenopausal women exists, practitioners extrapolate ipamorelin's efficacy from the MK-0677 dataset with the caveat that oral bioavailability dynamics differ from subcutaneous injection.

The Standard Ipamorelin Protocol for Perimenopause

The following protocol reflects current compounding pharmacy guidance and practitioner consensus. Evidence grade is labeled explicitly for each component.

Dose and Route

Starting dose: 100 mcg subcutaneously per injection. Evidence grade: practitioner consensus, extrapolated from the Raun et al. Dose-ranging study [5].

Titration target: 200 mcg per injection at 4 weeks if IGF-1 remains below the age-adjusted mid-normal range and the patient tolerates the starting dose. Some practitioners titrate to 300 mcg in women with very low baseline IGF-1 (below 100 ng/mL), but doses above 300 mcg per injection do not produce proportional IGF-1 gains and may increase water retention.

Subcutaneous injection into the periumbilical abdomen, lateral thigh, or outer deltoid delivers consistent absorption. Rotating sites prevents lipodystrophy. The injection volume is typically 0.1 to 0.2 mL using a 29-gauge, 0.5-inch insulin syringe.

Timing and Frequency

Inject at bedtime, at least 2 hours after the last meal, on an empty stomach. Dietary carbohydrates and free fatty acids suppress somatostatin tone and blunt GH pulse amplitude; fasting before injection preserves the response. A 2014 study in Growth Hormone and IGF Research confirmed that postprandial somatostatin inhibition reduces ghrelin-stimulated GH secretion by approximately 50% in healthy adults [7].

Five nights per week (Monday through Friday, or any consistent 5-of-7 pattern) is the standard frequency. Weekend breaks are not clinically required but reduce injection burden and may preserve receptor sensitivity, though no published trial has compared 5/7 vs. 7/7 dosing for ipamorelin specifically.

Cycle Length and Off-Periods

Run 12 to 20 weeks on, followed by a 4 to 8 week off period. The rationale is receptor desensitization. GHS-R1a undergoes agonist-induced internalization with continuous stimulation; pulsatile or cyclical dosing helps maintain receptor density at the cell surface. Evidence for this cycle structure comes from preclinical GHS-R1a internalization studies, not from clinical trials in women [8].

After the off period, most practitioners recheck IGF-1 before restarting to confirm return-to-baseline and recalibrate dosing.

Combining Ipamorelin with CJC-1295 (No-DAC)

CJC-1295 without DAC (also called Mod-GRF 1-29) is a growth hormone-releasing hormone (GHRH) analog. When injected alongside ipamorelin, it acts at the GHRH receptor simultaneously, producing a synergistic GH pulse through dual receptor stimulation. The combination is sometimes called a "two-key" approach: ipamorelin drives GHS-R1a; CJC-1295 no-DAC drives the GHRH receptor.

Combination dose: 100 mcg ipamorelin plus 100 mcg CJC-1295 no-DAC per injection, given simultaneously in the same syringe or in separate injections at the same site. Evidence grade: mechanistic rationale supported by the GHRH + GHRP combination data from Khorram et al. (Journal of Clinical Endocrinology and Metabolism, 1997), which showed additive IGF-1 elevation when both axes were stimulated simultaneously in elderly men [9].

Perimenopausal women using this combination typically see IGF-1 responses 20 to 30% higher than with ipamorelin alone, based on practitioner-reported cohort data rather than controlled trials.

The following decision framework helps prescribers choose between monotherapy and combination therapy:

| Patient Profile | Recommended Starting Approach | |---|---| | Mild GH decline (IGF-1 100 to 130 ng/mL), no sleep complaint | Ipamorelin 100 mcg monotherapy | | Moderate GH decline (IGF-1 70 to 100 ng/mL), poor sleep | Ipamorelin 200 mcg monotherapy | | Low IGF-1 (<70 ng/mL), marked body composition change | Ipamorelin 100 mcg + CJC-1295 no-DAC 100 mcg | | Concurrent HRT use, optimization goal | Ipamorelin 100 mcg + CJC-1295 no-DAC 100 mcg |

Ipamorelin and Hormone Replacement Therapy: Does Order Matter?

Many perimenopausal women arrive at ipamorelin after or alongside HRT initiation. Estrogen itself upregulates hepatic GH receptor expression and increases IGF-1 sensitivity, so women starting estradiol may see a modest IGF-1 rise from HRT alone before ipamorelin is added. A 2001 study by Weissberger et al. In Journal of Clinical Endocrinology and Metabolism found that transdermal estradiol raised IGF-1 by roughly 10% at 6 months in postmenopausal women, while oral estrogen actually suppressed IGF-1 due to first-pass hepatic effects on GH receptor binding proteins [10].

The clinical implication: women using oral estrogen formulations may need higher ipamorelin doses to achieve the same IGF-1 target as women on transdermal estradiol.

Progesterone, prescribed for endometrial protection or sleep, does not appear to meaningfully alter GH secretagogue response at standard doses. Testosterone therapy in women, increasingly used for libido and energy, also raises IGF-1 modestly and should be factored into IGF-1 target-setting.

Monitoring Labs: What to Check and When

Baseline (Before First Injection)

Obtain: serum IGF-1 (age-adjusted reference range), fasting insulin, fasting glucose, HbA1c, lipid panel, comprehensive metabolic panel, TSH, free T4, and a full sex hormone panel (FSH, LH, estradiol, progesterone, total and free testosterone, SHBG). A morning cortisol level is useful in women with suspected HPA axis dysregulation.

The Endocrine Society's adult GH deficiency guideline recommends IGF-1 as the primary biomarker for GH axis assessment and notes that an IGF-1 below the age-adjusted mid-normal range warrants further evaluation [3].

Week 6 to 8 Follow-Up Labs

Recheck: IGF-1, fasting glucose, HbA1c. GH has counter-regulatory effects on insulin; supra-physiological IGF-1 elevation can worsen insulin resistance. The Phase III trial of recombinant human GH (rhGH) in GH-deficient adults (N=166, Johannsson et al., Journal of Clinical Endocrinology and Metabolism, 1997) found that IGF-1 levels above 2 SD over the age-adjusted mean correlated with higher rates of glucose intolerance [11].

Target IGF-1 in the upper-third of the age-adjusted normal range. Aiming above the range is not the goal and increases safety risk.

Week 12 to 16 Follow-Up Labs

Full repeat of baseline panel, plus DXA scan if body composition changes are being tracked formally. A DXA scan at baseline and at 16 weeks provides objective lean mass and fat mass data, which is clinically more useful than weight alone given that GH promotes lean mass accrual alongside fat reduction.

Expected Timeline of Outcomes

Outcomes are graded by evidence level because the specific trial data for ipamorelin in perimenopausal women is sparse.

Sleep Quality (4 to 8 Weeks)

Patients commonly report improved sleep onset and subjective sleep depth within 4 weeks. The mechanistic basis is supported by research showing that GH secretagogues increase slow-wave sleep EEG amplitude. A placebo-controlled crossover study of the GHRH analog (N=10 healthy older men, Marshall et al., Journal of Clinical Endocrinology and Metabolism, 1996) showed a 27% increase in slow-wave sleep time compared to placebo during a single overnight application [12]. Evidence grade for ipamorelin specifically: mechanistic extrapolation; no RCT.

Body Composition (8 to 16 Weeks)

Lean mass changes typically become measurable by DXA at 12 to 16 weeks. The MK-0677 12-month trial cited above (Murphy et al.) produced 1.5 kg of fat-free mass gain and a 0.9 kg reduction in fat mass in elderly subjects [6]. Perimenopausal women, who have higher baseline adiposity than the Murphy trial population, may see proportionally different fat loss. Expect modest changes, not dramatic remodeling, in a single 16-week cycle.

IGF-1 Normalization (4 to 6 Weeks)

IGF-1 typically rises within 4 to 6 weeks of consistent dosing. The target is the upper-third of the age-adjusted reference range. Women whose baseline IGF-1 is below 80 ng/mL may need the combination protocol (ipamorelin + CJC-1295 no-DAC) to reach that target.

Recovery and Joint Comfort (6 to 12 Weeks)

GH promotes collagen synthesis in tendons and cartilage. Women report reduced joint stiffness and faster recovery from exercise at roughly 6 to 8 weeks. This is supported by mechanistic data on GH and collagen turnover (Doessing et al., Journal of Physiology, 2010), though no ipamorelin RCT has specifically measured tendon collagen synthesis [13].

Contraindications and Safety Considerations

Ipamorelin is contraindicated in women with active malignancy because GH and IGF-1 are mitogenic. Women with a personal history of hormone-sensitive cancers should not use GH secretagogues without oncology clearance.

Uncontrolled type 2 diabetes or fasting glucose above 126 mg/dL is a relative contraindication. GH is counter-regulatory to insulin; elevating GH axis activity in the setting of insulin resistance can worsen glycemic control. The FDA's prescribing information for approved GH preparations (e.g., somatropin) carries a warning for glucose intolerance [14].

Pregnancy is an absolute contraindication. Ipamorelin has no safety data in human pregnancy.

Common side effects at clinical doses include water retention (ankle edema, carpal tunnel-like symptoms), mild fatigue on first injection, and transient flushing. These typically resolve within 2 weeks of starting or after dose reduction.

Ipamorelin itself is not FDA-approved. It is available as a compounded preparation under physician prescription. The FDA issued a 2023 guidance on compounded drug products that affects GH secretagogue availability from 503B outsourcing facilities; practitioners should verify current compounding status with their pharmacy [15].

Practical Injection Protocol (Step-by-Step)

1. Remove the vial from refrigeration 10 minutes before injection to reduce injection-site discomfort.
2. Wipe the vial top with an alcohol swab. Allow 30 seconds to dry.
3. Draw the prescribed volume (typically 0.1 to 0.2 mL for a 1 mg/mL reconstituted solution) into a 29-gauge insulin syringe.
4. Pinch a small fold of skin at the injection site. Insert the needle at a 45-degree angle.
5. Inject slowly. Remove the needle and apply gentle pressure. Do not rub.
6. Rotate the injection site with each dose. Keep a rotation log.
7. Reconstituted peptide stored at 2 to 8°C is stable for 30 days. Bacteriostatic water extends stability to approximately 60 days.